RxDoctor Payments Data

Vu Tran, MD

Internal Medicine · Ruskin, FLNPI 1912961889

Payments from drug & device makers

$1,718,151in general payments, 2019–2025

Across 107 payments — averaging $16,057 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB SA$1.7M
  • Astellas Pharma US Inc$23
  • Novo Nordisk$19
  • AstraZeneca$15
  • Pfizer$15
  • GSK$15

What the payments were for

  • Food & beverage$87100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB SA102$1,718,064
Astellas Pharma US Inc1$23
Novo Nordisk1$19
AstraZeneca1$15
Pfizer1$15
GSK1$15

How this compares

$1,718,151 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$32,229
Medicare patients
104
Services billed
1,404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban188$151,831
ProliaDenosumab40$68,477
JardianceEmpagliflozin48$68,351
OzempicSemaglutide56$66,866
XareltoRivaroxaban31$27,602
Breo ElliptaFluticasone/Vilanterol41$21,176
MyrbetriqMirabegron37$20,476
SymbicortBudesonide/Formoterol Fumarate58$14,804
LinzessLinaclotide13$7,759
Azelastine Hcl287$5,963
Fluticasone Propionate481$5,603
Levothyroxine Sodium524$5,106
LumiganBimatoprost12$4,562
Celecoxib285$4,042
Diclofenac Sodium145$4,011

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$151,831188 claims
Novo NordiskOzempic$19$66,86656 claims
GSKBreo Ellipta$15$21,17641 claims
Astellas Pharma US IncMyrbetriq$23$20,47637 claims
AstraZenecaSymbicort$15$14,80458 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Ruskin

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →